I agree that this site is using cookies. You can find further informations here.
X
Jones, Aksana K.
22  results:
Search for persons X
?
1

Population Pharmacokinetics of a Monthly Buprenorphine Depo..:

Jones, Aksana K. ; Ngaimisi, Eliford ; Gopalakrishnan, Mathangi..
Clinical Pharmacokinetics.  60 (2020)  4 - p. 527-540 , 2020
Link: https://doi.org/10.1007/..
 
?
2

Power Determination During Drug Development: Is Optimizing ..:

Jones, Aksana K. ; Salem, Ahmed Hamed ; Freise, Kevin J.
CPT: Pharmacometrics & Systems Pharmacology.  8 (2019)  3 - p. 138-145 , 2019
Link: https://doi.org/10.1002/..
 
?
3

Population Pharmacokinetics of Clofarabine as Part of Pretr..:

Wang, Hechuan ; Jones, Aksana K. ; Dvorak, Christopher C....
Biology of Blood and Marrow Transplantation.  25 (2019)  8 - p. 1603-1610 , 2019
Link: https://doi.org/10.1016/..
 
?
4

Venetoclax does not prolong the QT interval in patients wit..:

Freise, Kevin J. ; Dunbar, Martin ; Jones, Aksana K....
Cancer Chemotherapy and Pharmacology.  78 (2016)  4 - p. 847-853 , 2016
Link: https://doi.org/10.1007/..
 
?
5

Clinical Predictors of Venetoclax Pharmacokinetics in Chron..:

Jones, Aksana K. ; Freise, Kevin J. ; Agarwal, Suresh K....
The AAPS Journal.  18 (2016)  5 - p. 1192-1202 , 2016
Link: https://doi.org/10.1208/..
 
?
6

Impact of Venetoclax Exposure on Clinical Efficacy and Safe..:

Freise, Kevin J. ; Jones, Aksana K. ; Eckert, Doerthe...
Clinical Pharmacokinetics.  56 (2016)  5 - p. 515-523 , 2016
Link: https://doi.org/10.1007/..
 
?
7

Relationship between venetoclax exposure, rituximab coadmin..:

Freise, Kevin J. ; Jones, Aksana K. ; Menon, Rajeev M....
Hematological Oncology.  35 (2016)  4 - p. 679-684 , 2016
Link: https://doi.org/10.1002/..
 
?
8

Population Pharmacokinetics of a Monthly Buprenorphine Depo..:

Jones, Aksana K ; Ngaimisi, Eliford ; Gopalakrishnan, Mathangi..
Clinical Pharmacokinetics.  , 2020
Link: http://hdl.handle.net/10..
 
?
9

POPULATION PHARMACOKINETICS OF CLOFARABINE AS PART OF PRE-T..:

Wang, Hechuan ; Jones, Aksana K ; Dvorak, Christopher C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291704/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
10

Population Pharmacokinetics of Clofarabine as Part of Pretr..:

Wang, Hechuan ; Jones, Aksana K ; Dvorak, Christopher C...
qt8qq7m9q4.  , 2019
Link: https://escholarship.org..
 
?
11

Power Determination During Drug Development: Is Optimizing ..:

Jones, Aksana K ; Salem, Ahmed Hamed ; Freise, Kevin J
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430154/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
12

Power Determination During Drug Development: Is Optimizing ..:

Aksana K. Jones ; Ahmed Hamed Salem ; Kevin J. Freise
https://doi.org/10.1002/psp4.12380.  , 2019
Link: https://doi.org/10.1002/..
 
?
13

Sputum lipoarabinomannan (LAM) as a biomarker to determine ..:

Jones, Aksana ; Saini, Jay ; Kriel, Belinda...
BMC Infectious Diseases.  22 (2022)  1 - p. , 2022
Link: https://doi.org/10.1186/..
 
?
14

Dose selection for fremanezumab (AJOVY) phase 3 pediatric m..:

Cohen-Barak, Orit ; Radivojevic, Andrijana ; Jones, Aksana...
Cephalalgia.  41 (2021)  10 - p. 1065-1074 , 2021
Link: https://doi.org/10.1177/..
 
?
15

Scaling Approaches for Pediatric Dose Selection: The Freman..:

Jones, Aksana ; Cohen-Barak, Orit ; Radivojevic, Andrijana.
Pharmaceutics.  13 (2021)  6 - p. 785 , 2021
Link: https://doi.org/10.3390/..
 
1-15